Revelation Biosciences, Inc. (NASDAQ:REVB) Shares Shorted: Short Interest Down 56.0% in September

Revelation Biosciences, Inc. (NASDAQ:REVB) saw a significant drop in short interest in September. As of September 15th, there was short interest totaling 256 shares, a drop of 56.0% from the August 31st total of 582 shares. Currently, 0.0% of the company’s stock are short sold. Based on an average trading volume of 14,833 shares, the short-interest ratio is presently 0.0 days.

Revelation Biosciences Trading Down 5.3%

Shares of REVB stock traded down $0.05 during mid-day trading on Tuesday, reaching $0.81. The stock had a trading volume of 52,268 shares, compared to its average volume of 23,476. Revelation Biosciences has a 1-year low of $0.81 and a 1-year high of $6.76. The firm has a market cap of $3.24 million, a price-to-earnings ratio of -0.07 and a beta of -0.14. The business’s fifty day moving average is $1.02 and its 200-day moving average is $1.07.

Revelation Biosciences (NASDAQ:REVB) last released its earnings results on Thursday, August 6th. The company reported ($0.87) EPS for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.01. On average, analysts forecast that Revelation Biosciences will post -5.18 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings downgraded shares of Revelation Biosciences from a “sell (e+)” rating to a “sell (e)” rating in a research report on Tuesday, August 25th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Revelation Biosciences currently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Revelation Biosciences stock. Sabby Management LLC raised its stake in Revelation Biosciences, Inc. (NASDAQ:REVB) by 192.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 605,702 shares of the company’s stock after acquiring an additional 398,651 shares during the quarter. Revelation Biosciences makes up approximately 0.7% of Sabby Management LLC’s investment portfolio, making the stock its 8th largest position. Sabby Management LLC owned approximately 8.78% of Revelation Biosciences worth $484,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 12.80% of the company’s stock.

About Revelation Biosciences

Revelation Biosciences, Inc is a clinical-stage biotechnology company focused on developing immunologic therapies for diseases with significant unmet medical needs. The company’s research is centered on therapeutics designed to stimulate or modulate the body’s innate immune system, the first line of defense against infection and other disease processes.

Its development pipeline has included REVTx-99, an investigational intranasal therapy based on a proprietary beta-glucan formulation. The candidate has been studied for its potential to help prevent or reduce the severity of respiratory viral infections and associated complications, including acute respiratory distress.